A Clinical Evaluation of Baofeikang Granule in Combined Pulmonary Fibrosis and Emphysema Treatment

• Status: Unknown status
• Trial end date: 2019-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to confirm the efficacy and safety of BaofeiKang Granule in the treatment of Combined Pulmonary Fibrosis and Emphysema patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Municipal Science & Technology Commission
• Treatments: Anti-Asthmatic Agents; Anti-Inflammatory Agents; Expectorants

Criteria

Inclusion Criteria:

1. conform to Combined Pulmonary Fibrosis and Emphysema Treatment diagnostic criteria;

2. conform to Qi and yin deficiency, phlegm and blood stasis syndrome diagnosis standard;

3. Patients with non acute episode;

4. Age between 45-75 (including 45 and 75);

5. signed the informed consent.

Exclusion Criteria:

1. Combined upper and lower respiratory infection, pulmonary tuberculosis, lung cancer or other lung diseases;

2. Combined with diabetes, cardiovascular, liver, kidney or hematopoietic system diseases, psychiatric patients;

3. Pregnancy and lactation patients;

4. Allergic to the subjects of the medicine.

Rejection criteria:

1. do not meet the inclusion criteria after entering the group;

2. the discovery of serious physical illness after entering the group;

3. do not follow the program medication of patients;